Precision BioSciences Announces Allowance of Eleventh U.S. Patent Application Related to Genome Editing Nucleases
Published: Oct 29, 2012
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application 13/457,041 (“the ‘041 Application”). The allowed claims relate to materials and substitutions used for the creation of enzymes capable of modifying endogenous locations within a complex genome. These materials and substitutions constitute an important aspect of Precision’s genome engineering technologies, known collectively as the Directed Nuclease Editor or DNE.